



***The Rosalind and Morris Goodman
Cancer Research Centre***

*Faculty of Medicine
McGill University*

Highlight of the Year 2011

*Presented by:
Michel L. Tremblay
Peter Siegel*

Table of Contents

GCRC Summary	page 3
GCRC at a Glance in 2011	page 6
Section I: Unit Status Update	
GCRC mission and objectives	page 8
Appendix I List of academic staff	page 9
Appendix II Honors, Awards, and Prizes	page 10
Section II: Grants, publications, and service outside of McGill	
Appendix III Grants	page 13
Appendix IV Publications	page 27
Appendix V Academic and community engagement	page 41
Section III: Confidential Information	
Appendix VI Consulting Activities Table	page 49

Goodman Cancer Research Centre Summary

Centre organization: Over the past year, a number of changes, developments and accomplishments have taken place at the Goodman Cancer Research Centre (GCRC). These have included: an overhaul of the administrative structure, renewal of a FRQS grant for GCRC infrastructure operations, acquiring a number of important team and individual grants, pursuing research excellence through publishing key discoveries in high impact journals, providing multidisciplinary training opportunities for our graduate students and post-doctoral fellows, strengthening the translational research aspect of GCRC discoveries and intensification fundraising activities.

The GCRC's administrative structure has been strengthened to accommodate the rapid expansion of the Centre's infrastructure and increase in research personnel. Mr. J Hendlisz, former director of the Douglas Hospital, was recruited to initiate the restructuring of the Centre's operations, to develop better integration of GCRC services with those of the Faculty and the University, and to initiate interactions with the directorships of the affiliated research hospital Centre at McGill in order to prepare future development among the various McGill University cancer organization consortiums.

The thematic division of GCRC into 5 units: *Development Biology and Cancer, Breast Cancer, Stem cells/signaling in Cancer, Metabolism and Cancer, and cell apoptosis/DNA damage*, has resulted in a critical mass of specialists who are accelerating discoveries in these fields of research, initiating meaningful collaborations with clinical and basic scientists, and becoming more competitive in team grant applications. It is noteworthy that, for the first time in the 20-year history of the Centre, each of the PIs has one or multiple collaborations with their clinical counterparts at the MUHC RI, the Jewish General Hospital or elsewhere in the world.

Research excellence: One of the most important highlights in 2011 was the renewal of our FRQS group status. Last year, due to the exceptional performance of the GCRC, the Centre was the only FRQS-funded academic research unit (*Centres, Groupes and Réseaux*) to receive an increase to the annual operating budget. We were granted \$2,125,000 (\$425,000.00 per year for the next five years). Other important team awards included: 1) a team grant of \$1.3 million from the Quebec Consortium for Drug Delivery led by Dr. M Park for the development of integrated tumor-micro environmental classifiers for personalized therapy targeting, 2) a 3-year team grant of \$4 million from CIHR/Terry Fox RI New Frontiers Program in Cancer led by Dr. M.L. Tremblay was awarded to the metabolism and cancer group at GCRC to pursue the role of AMPK in cancer metabolism. This award was particularly important since it represented the first team grant secured by the metabolism and cancer group. Moreover, it also represented a second CIHR/TFRI New Frontiers Team Grant at the GCRC, adding to the team grant held by the breast cancer group, led by Dr. W.J. Muller, which was renewed in 2010 (2010-2014). Thus, the GCRC is the only research Centre in Canada to hold two of these prestigious grants, 3) the Terry Fox Research Institute extended a major grant of more than \$400,000 to a research team from the MUHC (Drs Gagnon and McDonald) and GCRC (Drs. Tremblay and Pelletier) for the development of new blood based predictors in cancer cachexia from lung and pancreatic cancer patients, and 4) a team composed of Drs. ML Tremblay (GCRC), B Gagnon (MUHC), and N McDonald (MUHC), in partnership with clinicians and scientists from Alberta, England and Spain, received a \$300,000 grant (CIHR) to initiate the largest international network on cancer cachexia.

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

The successes in funding obtained by the members of the GCRC, is the result of innovative research, an interactive network of colleagues/collaborators and the existence of outstanding infrastructure. It is through this unique environment that our research programs can advance and the high caliber and excellence in research can be maintained. In 2011, the GCRC completed the establishment of the first Metabolomic Core facility dedicated to cancer research in Canada, which was built with a \$10 million CFI grant obtained with our RI-MUHC colleagues in 2010. In addition, and among other exceptional outputs from the Centre, GCRC PIs have filed several patents and licensing agreements. They have also collectively published over 102 papers and book chapters. Many of which were published in the best scientific journals in the world: Nature, Science, Nature Cancer Review, Cell metabolism, PNAS and others. The examples of the diversified and competitive research findings published by the members of the GCRC can be found in the accompanying appendices.

Training: In 2011, the GCRC trained 112 graduate students, 57 postdoctoral fellows and 19 summer students. To support these young researchers, the GCRC - in collaboration with the Segal Cancer Centre (SCC) - established the McGill Integrated Cancer Research Training Program (MICRTP) in 2009 and secured funding from CIHR along with a commitment from its partners (GCRC, SCC and MUHC RI) until 2014. This five-year training grant (only four were given in Canada) represents a major internal funding opportunity to our trainees and provides a platform for delivery of exceptional training activities. Moreover, Défi Canderel continued its remarkable support of the Centre with their ongoing fundraiser. The funds collected by this annual “fun run” event in 2011 were allocated towards the stipends of our trainees. In addition to securing funds for GCRC trainees, the Centre has organized several events inside our training program. Two major ones included: 1) the Montreal International Symposium on Angiogenesis and Metastasis 2011 (Montreal; June 15-17) led by Dr. Beauchemin. The meeting was focused on colorectal cancer and liver metastasis, brought world-renown scientists in this field from around the world and had 200 attendees, 2) a retreat on metabolism and cancer (Gauld Estate; June 20-23) organized by Dr. R. Jones (GCRC, Metabolism Group). This event was crucial in providing a platform for more than 50 trainees to learn about metabolomics, listen to talks and present their own work on this topic. Furthermore, GCRC continued to deliver the Clinical and Experimental Oncology Course. Unique in Canada, this course includes basic and clinical lectures on different tumor sites, latest discoveries in cancer diagnosis and treatment, and allows graduate students to attend tumors board meetings. The attendance in the course is at capacity.

Translating basic research to the clinic: GCRC has made significant progress in their goal of bridging basic research with the clinic and this translational research is now increasingly performed at several levels: 1) direct collaborations between our researchers and colleagues from McGill affiliated hospital research institutes have been established; 2) the Centre appointed a new member-clinician scientist, whose laboratory is located at GCRC. In partnerships with the RI-MUHC and the Dept. of Surgery, Dr. George Zogopoulos, an MD/PhD was recruited to GCRC to work on pancreatic cancer; 3) Laboratory for Therapeutic Development has been established at GCRC under the leadership of Dr. Gordon Shore. The objective of this is venture, which received 5 million dollars in funding Genome Quebec and CQDM, is to identify novel therapeutics for human multiple myeloma and is done in close collaboration with Astra-Zeneca, Merck and Pfizer; and 4) Contracts and collaborations with the pharmaceutical and biotechnology sectors are continuing. Companies such as Labopharm, Kanek, Mispro,

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

Oncozyme and Celldex Therapeutics have direct partnerships with some of the GCRC researchers.

Public outreach/education: With respect to community involvement, we would like to touch on two different aspects of public awareness action that focus on our research and fundraising efforts. The first initiative reflects a genuine desire to keep the public informed about the recent developments in cancer research. In doing so, we strive to engage the public and propagate the idea that laypeople can effectively lobby government and funding agencies to maintain sufficient grant support for current and future research activities. The second activity involves using many of our informational events as a means of increasing philanthropic gifts to the GCRC. It is important to state that all of these activities are organized and performed with the consent and collaboration of the Faculty and the University's DAR office. Last year we continued to organize the very successful Goodman evening public lectures. With attendance of well over 200 persons per evening, this is rapidly becoming an established go-to event for the general public as well as patients in the Montreal area that are affected by cancer. The 2011 lectures included: 1) on March 24th, Stem Cells and Cancer lecture, 2) on Oct 18th, Cancer: From Chaos to Quality Care lecture, 3) on Nov 22nd, Pancreatic Cancer lecture. A noteworthy lecture was held on May 16th, in which the public forum was organized around a conference by Dr. Marla Shapiro, a McGill Faculty of Medicine alumni, physician, cancer survivor and CTV host of the "Health Show". More than 300 people attended and over \$50,000 was raised to support research at the GCRC.

Fundraising: Finally, our benefactors, Morris and Rosalind Goodman, have continued their tremendous involvement in support of GCRC and organized a very successful fundraising/awareness campaigns in the form of a YouTube video (over 500,000 views). This project has had an amazing response from the public and has dramatically raised awareness of the GCRC. For their tireless involvement and support, both Rosalind and Morris Goodman received *honoris causa* doctorate degrees at the spring Health Science Convocation Ceremony at McGill University on Tuesday, May 31, 2011. This was a real opportunity for our community to gratefully acknowledge the Goodman's extraordinary support to the Centre and the University.

Future Objectives and Conclusion:

In the past twelve months, the Centre has made important changes in many scientific and administrative directions. We are delighted that our constant efforts have positioned the GCRC as a top research institution in Quebec, Canada and internationally. Many challenges and opportunities await us in 2012, which include the naming of a new director and the development of a new 5-year plan for the Centre as envisioned by the new leadership. We will continue to strengthen our interactions with our many partners including the external advisory board of the GCRC, the life sciences complex researchers, Departments within the Faculties of Medicine and Science, the Faculty and University administrations, our current and expanded clinical partners at McGill affiliated hospitals and in many horizons outside McGill University.

It is with great pride that we are looking at our accomplishment and with confidence that we will continue to make a difference in all aspects of our mission objectives. With this exciting future in view, we can only be enthusiastic with the coming year and beyond.

Drs. Michel L. Tremblay and Peter M. Siegel.

**THE GOODMAN CANCER RESEARCH CENTRE
AT A GLANCE**

January 1, 2001 – December 31, 2011

- The Centre is comprised of 25 principal investigators who are full members:
 - 14 Full Professors, 3 Associate Professors, 8 Assistant Professors
- PIs are appointed in 7 different Departments:
 - Biochemistry, Oncology, Medicine, Physiology, Human Genetics, Surgery, and Computer Science
- All our members are contributing to administration, teaching and community service
- Members have various forms of salary support
 - 10 Salary Support Awards, 4 Canada Research Chairs, 8 McGill Chairs/Awards
- The Centre also has 30 associate members
- Total number of Goodman Centre trainees is 188:
 - graduate students: 112 (41 MSc, and 71 PhD), Post-docs: 57; and Summer Students: 19
- Total number of administrative and operations staff: 23, casual staff: 20
- Total number of individuals involved in research in the Centre: 308
 - PIs, Technicians, Research Assistant and Associates, Post-docs, Graduate Students, Summer Students and Casual Staff
- Number of publications: 102 publications (manuscripts and book chapters)
- 16 PIs participate in team grants
- Total administrative budget (including infrastructure grants) for the Centre: \$1.5 million
- All full members secured external research funding for a total of \$ 15 million
- McGill Integrated Cancer Research Training Program is run by the Centre with an annual budget of \$ 0.5 million
- The Centre offers Public Lectures to general audience throughout the year
- Total amount of money fundraised: \$ 0.9 million

Section I

Unit Status Update

GCRC mission and objectives

The mission:

The mission of the Goodman Cancer Research Centre has remained the same since its establishment in 1978. The three major elements of this mission are as follows:

- 1) To bring together internationally renowned scientists devoted to cancer research and provide them with the best resources available so that they are poised to fully contribute to the worldwide effort to cure cancer.
- 2) To provide an internationally recognized state-of-the-art training platform for the next generation of researchers.
- 3) To promote the importance of fundamental basic research to the advancement of our molecular understanding of cancer, prevention, prognosis and treatment to both the public and medical community.

The objectives:

In the past year, our specific objectives focused on:

- Restructuring the administration of the Centre to improve processes
- Advancing research infrastructure and collaborations
- Building Metabolomics core facility dedicated to studying metabolism and cancer
- Securing GCRC infrastructure and a team grants
- Strengthening basic - clinical research interactions
- Recruitment of a physician-researcher
- Continuing the delivery of the McGill Integrated Cancer Research Training Program
- Creating public awareness about the cancer issues
- Increasing fundraising efforts to strengthen the sustainability of the Centre to maintain growth and the quality of our infrastructures

Appendix I – List of academic staff

Professor, Director (outgoing)	TREMBLAY, Michel	(on leave)
Professor	BEAUCHEMIN, Nicole	(on leave)
Professor	BRANTON, Philip	(active)
Professor	GIGUERE, Vincent	(active)
Professor	GROS, Philippe	(active)
Professor	HALLETT, Michael	(active)
Professor	MULLER, William	(active)
Professor	NEPVEU, Alain	(active)
Professor	PARK, Morag	(active)
Professor	PELLETIER, Jerry	(active)
Professor	SHORE, Gordon	(active)
Professor	SONENBERG, Nahum	(active)
Professor	YANG, Xiang-Jiao	(active)
Professor	ZANNIS-HADJOPOULOS, Maria	(on leave)
Associate Professor	BOUCHARD, Maxime	(active)
Associate Professor	PAUSE, Arnim	(active)
Associate Professor	SIEGEL, Peter	(active)
Assistant Professor	DUCHAIINE, Thomas	(active)
Assistant Professor	GALLOUZI, Imed	(active)
Assistant Professor	JONES, Russell	(active)
Assistant Professor	McCAFFREY, Luke	(active)
Assistant Professor	ST-PIERRE, Julie	(active)
Assistant Professor	TEODORO, Jose	(active)
Assistant Professor	YAMANAKA, Yojiro	(active)
Assistant Professor/MD	ZOGOPOULOS, George	(active)

Appendix II – Honors, Awards, and Prizes

Full members of the Centre held a total of 36 Honors/Awards/Prizes in 2011 of which 10 were received in this reporting period

BOUCHARD, Maxime, Dr.

2008-2013 Awarded the Canadian Research Chair on Developmental Genetics of the Urogenital System, Government of Canada.

BRANTON, Philip, Dr.

1996-present Gilman Cheney Professor of Biochemistry, McGill University

2002-present Member, Academy of Science of the Royal Society of Canada

2011 Canadian Cancer Research Alliance (CCRA) Award for Exceptional Leadership in Cancer Research

DUCHAIINE, Thomas, Dr.

2011-2015 Chercheur-boursier Junior 2 (Salary Award)

2007-2011 Chercheur-boursier Junior 1 (Salary Award)
FRSQ, Volet Recherche fondamentale

GALLOUZI, Imed, Dr.

2008-2013 TierII Canadian Research Chair, Salary Award

GIGUERE, Vincent, Dr.

2009-present Fellow of the Royal Society of Canada (FRSC), Academy of Sciences, Life Science Division, Discipline of Molecular Biology and Genetics (2009)

GROS, Philippe, Dr.

2010-2017 McGill University, James McGill Professorship

2011 Foundation of Stars, 2011 Prize for Scientific Career Achievements

2003-present Fellow of the Royal Society of Canada

JONES, Russell, Dr.

2009-2014 New Investigator Award (MOP-95379), “Role of the AMP-activated protein kinase (AMPK) in stress resistance and cancer,” Canadian Institutes of Health Research (CIHR), Salary Award.

2009-2013 Chercheurs-boursiers I Award (award declined), “Role of the AMPK-activated protein kinase in metabolic regulation and cancer,” Fonds de recherché du santé du Quebec (FRSQ), Salary Award.

MULLER, William, Dr.

2011-present Fellow of the Royal Society of Canada

2002-2016 CRC Chair in Molecular Oncology, McGill University

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

NEPVEU, Alain, Dr.

2005-2012 James McGill Professor, McGill University

PARK, Morag, Dr.

2007-present Fellow of the Royal Society of Canada

2006-2013 James McGill Professor, McGill University

2003-present Diane and Sal Guerrero Chair in Cancer Genetics

PAUSE, Arnim, Dr.

2003-2013 Canada Research Chair in Molecular Oncology

PELLETIER, Jerry, Dr.

2005-2012 James McGill Professor, McGill University.

SIEGEL, Peter, Dr.

2010-2012 Research Scholars – Junior 2, FRSQ Salary Support Award, McGill University

SONENBERG, Nahum, Dr.

2011 The Centenary Award, Biochemical Society (UK) Awards

2006-present Member of the Royal Society of London, UK

2006-present Member of the American Academy of Arts and Sciences

1992-present Fellow of the Royal Society of Canada

ST-PIERRE, Julie, Dr.

2010-2014 FRSQ Chercheur-Boursier Junior 1, Salary Support Award

TEODORO, Jose, Dr.

2008-2013 CIHR New Investigator Award

TREMBLAY, Michel, Dr.

2006-present Fellow of the Royal Society of Canada

2005-2015 Jeanne and J-Louis Lévesque Chair in Cancer Research

2004-2015 James McGill Professor, McGill University

YAMANAKA, Yojiro, Dr.

2011 Maud Menten New Investigator award, Finalist, Research Award

ZOGOPOULOS, George, Dr.

2011-2014 Simone and Morris Fast Award for Oncology, McGill University Health Centre

2011-2014 Tomlinson Young Surgeons' Award, McGill University

2011-2014 New Investigator Funding, the Research Institute of the McGill University Health Centre and the Rosalind and Morris Goodman Cancer Research, GZ (PI)

2011 New Investigator Equipment Funding, the Research Institute of the McGill University Health Centre, GZ (PI)

Section II

**Grants, publications,
and service outside of McGill**

Appendix III – Research Grants Obtained

It is noteworthy that research funding for the Centre continued to increase for the 12th year in a row, with the tally of peer-reviewed funding of the GCRC PIs now surpassing 15 million annually. In these days of funding restrictions in most granting agencies, it is remarkable that all 25 principal investigators at the GCRC hold peer review funding (table below). Together, 2011 has been the most successful granting year in the GCRC history. Indeed, there are many reasons to be optimistic for future research programs of the Centre. With the increasing number of successful translation, multidisciplinary and collaborative grants secured by the members of the GCRC, we are extremely well positioned to benefit from the new changes ongoing in the funding program both at CIHR and the new provincial FRS agencies.

GCRC

Agency	Type	Grant #	Title	Funding Period	Amount 2011
FRSQ	Infrastructure		Groupe de recherche sur le cancer de McGill	04/2011-03/2015	\$318,750
FRSQ	Infrastructure		Groupe de recherche sur le cancer de McGill	04/2007-03/2011	\$100,000
CIHR/FRSQ	Strategic Training Initiative		The CIHR/FRSQ Training Program in Cancer Research at McGill (Training grant of the GCRC, Segal Cancer Centre and MUHC) (MICTRP)	04/2009-03/2015	\$325,000

BEAUCHEMIN, Nicole

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CQDM	CQDM		SN-38 (or 5-FU) drug encapsulation in liposomes transported by magnetotactic bacteria for localized colorectal cancer treatment	09/2011-08/2014	\$3,333
CIHR/TFRI	Oncometabol . Team Grant		Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
CRS	Operating		Genetic Control of Susceptibility to Colon Cancer	09/2010-08/2012	\$60,000
CIHR	Operating		CEACAM1 in colon cancer progression	04/2008-03/2012	\$177,253

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

CIHR	Operating		Metabolic functions of the PTPase SHP-1 in insulin target tissues	04/2007-03/2012	\$17,000
CIHR	Operating		CEACAM1 as a regulator of normal and tumor angiogenesis	10/2007-09/2011	\$35,285

BOUCHARD, Maxime

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CRC	CRC Chair		Developmental genetics of the urogenital system	10/2008-09/2013	\$25,000
CRS	Operating		Gata3 and the Androgen Receptor Response in Prostate Cancer		\$20,000
CIHR	Operating		Transcriptional network of urogenital system development in the mouse	09/2007-08/2012	\$130,357
CIHR	Operating		LAR-family receptor tyrosine phosphatases in urogenital system malformations	09/2007-08/2012	\$124,779
KFC	Biomedical Research Grant		Mouse models of urogenital system developmental diseases	07/2010-06/2012	\$50,000
CRS			Role of Gata3 in prostate cancer	08/2010-07/2011	\$35,000

BRANTON, Philip

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Role of the E4orf6/E1B55K E3 ubiquitin ligase in the adenovirus life cycle	04/2010-03/2015	\$190,673
CIHR	Operating		Mechanism of action of the adenovirus death protein E4orf4	04/2009-03/2014	\$144,141

DUCHAIINE, Thomas

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Mechanism of microRNA action in translation and mRNA decay	04/2009-03/2013	\$31,385
CIHR	Operating		RNAi-mediated Genetic Regulation Loops	03/2008-03/2013	\$125,323
CFI	Leaders Opportunity Fund		CFI Leaders Opportunity Award	09/2007-09/2012	\$90,966
NSERC	Discovery Grant		The role of tandem tudor domain proteins in RNAi	04/2007-03/2012	\$28,170

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

GALLOUZI, Imed

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		The RNA binding protein HuR is a key player in muscle cell differentiation	09/2008-09/2013	\$135,184
NSERC	Discovery Grant		Identification of the posttranscriptional regulatory network of the pro-inflammatory cytokine HMGB1	07/2009-06/2014	\$56,000
NCIC	Operating		The RNA binding protein HuR is a key player in cancer induced muscle wasting	07/2007-06/2012	\$128,000

GIGUERE, Vincent

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Molecular and genetic analysis of ERR function in breast cancer	10/2011-09/2016	\$41,304
CIHR	Operating		Transcriptional control of metabolism by estrogen related receptors (ERRs)	04/2011-03/2016	
CIHR/TFRI	Oncometabol. Team Grant		Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
CCSRI	TFFNFPPG Team Grant	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	
GQ	Pilot Project	wSt-Pierre	Metabolomics of ErbB2-induced breast tumors	10/2010-09/2012	
CIHR	Operating		Genetic and functional analyses of orphan nuclear receptor functions	10/2007-09/2012	\$194,432
US Army	Fellowship		Novel Androgen Receptor Cofactor: Potential Action in Prostate Cancer Pathogenesis	08/2009-07/2011	\$30,981

GROS, Philippe

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Role of Vangl proteins in normal development and in neural tube defects	10/2011-09/2016	\$35,750
NIH (USA)	Investigator Initiated Research		Genetic determinants of susceptibility to mycobacterial infections	04/2011-12/2015	\$164,062

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

CIHR	Team Grant		CIHR Team in ENU mutagenesis and infectious diseases	09/2008-08/2013	\$150,000
CRS	Operating		Genetic control of susceptibility to colon cancer development	09/2010-08/2012	\$60,000
CIHR	Operating		Genetic determinants of susceptibility to mycobacterial infections	10/2010-09/2015	\$162,443
CIHR	Operating		Role of Vangl proteins in neural tube defects and other aspects of development	04/2006-03/2011	\$32,900
CIHR	Operating		Genetic determinants of susceptibility to blood-stage malaria	04/2006-03/2011	\$35,550
CIHR	Team Grant	wKain	CIHR Team grant in malaria	04/2006-03/2011	\$43,581
CIHR	Team Grant	wRaymond	CIHR Team Grant in Fungal Pathogenesis	04/2006-03/2011	\$21,500

HALLETT, Michael

Agency	Type	Grant #	Title	Funding Period	Amount 2011
NSERC	Discovery		Signature Analysis Tools for the Life Sciences	04/2011-03/2016	\$30,000
CIHR	STIHR		Integrative Approaches to Human Health	04/2009-03/2015	\$223,750
CQDM		wPark	Development of integrated tumor-microenvironmental classifiers for personalized therapy targeting	01/2012-12/2014	
NCIC	PPG	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	04/2009-03/2014	
GQ	Genomics Research in Human Health		Next Generation Predictive Signatures for Breast Cancer	07/2010-07/2013	\$483,186
FRSQ	Pfizer fonds d'innovation	wPark	Tests pronostiques pour le cancer du sein basés sur l'immunohistochimie intégrant les composantes épithéliales et stromales	07/2010-07/2013	
CCSRI	CBCRA Predictive Oncology Grant	wPark	Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative	04/2011-03/2013	

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			disease		
CIHR	Team Grant	wSzyf	Whole epigenome profiling of epigenetic marks of maternal depression and its impact on the offspring epigenome	04/2010-03/2013	\$21,000
GQ	International Collaborations Program in Genomics	wBergeron	Proteomics of the Human Liver in Health and Disease	10/2011-09/2012	\$4,250
GQ		wKimmins	Determining the role of the paternal epigenome in offspring health	08/2010-08/2012	\$17,000
FRSQ	Q-CROC	wBatist	Identification et validation de biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	04/2009-03/2012	\$17,000
CIHR	POP	wNepveu	Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool	04/2011-03/2012	
NSERC	CHRP	wThomas	Chemical correctors of deltaF508 CFTR trafficking	04/2009-03/2012	\$45,000
QBCF	CRS Strategic Grant	wPark	Gene expression and phenotypic characterization of circulating tumor cells: Towards an understanding of the seeds of metastasis	08/2008-08/2011	
CIHR	Team Grant	wSiegel	CIHR Team in Cancer Progression and Metastasis	07/2006-06/2011	
NSERC	Discovery		Molecular Signatures of Synergy	04/2010-03/2011	\$6,500

JONES, Russell

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Catalyst Grant		Development of novel animal models to study the impact of metabolism on aging: Investigating the role of the AMP-activated protein kinase (AMPK)	04/2011-03/2012	\$37,144
CIHR/TFRI	Oncometabol. Team Grant		Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
CCSRI			Metabolic control points in	07/2010-	\$137,759

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			lymphomagenesis	06/2013	
CIHR	Operating		Role of the AMP-activated protein kinase (AMPK) in stress resistance and cancer	04/2009-03/2013	\$133,433
CFI	Leaders Opportunity Fund		Metabolism and Cancer: Studying the integration of metabolism and signal transduction in tumourigenesis	09/2009-08/2014	\$32,000
CIHR	New Investigator Award		Role of the AMP-activated protein kinase (AMPK) in stress resistance and cancer	04/2009-03/2014	\$60,000

McCAFFREY, Luke

Agency	Type	Grant #	Title	Funding Period	Amount 2011
TFF	New Investigator Award		Epithelial polarity in tumor invasion and metastasis	10/2011-09/2014	\$146,371
McGill	Start-up Funds		Epithelial polarity in mammary gland development and cancer	08/2010-07/2012	\$95,000

MULLER, William

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		The role of ErbB2-14-3-3 sigma signaling axis in cancer and development	10/2010-09/2015	\$155,694
NIH (USA)	Program Project		Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation	09/2010-08/2015	\$191,580
NIH (USA)	Program Project		Mechanisms of breast cancer progression	09/2009-08/2014	\$112,594
CCSRI	TFFNFPPG Team Grant		Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	\$1,030,684
CIHR	Operating		The role of Epidermal Growth Factor Receptor Family in mammary tumorigenesis and metastasis	04/2009-03/2014	\$155,053
GQ	Research Grant	wHallett	Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	
CIHR	Operating		The role of PI3K coupled signaling pathways in mammary tumorigenesis	08/2008-09/2013	\$128,630
CBCRA	Research Grant		The role of ShcA and c-Src signaling pathways in ErbB-2	07/2008-06/2013	\$148,984

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			mammary tumor progression		
CRS	Operating		Role of Akt family signaling in ErbB2 mammary tumour progression	09/2010-08/2012	\$60,000
CIHR	Team Grant	wSiegel	CIHR Team in Models of Cancer Progression and Metastasis	04/2006-03/2011	

NEPVEU, Alain

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Transcription and Translation Synthesis	09/2009-08/2014	\$139,935
NCIC	Operating		Function and Modulation of CUX1 in Cell Cycle Progression	07/2008-06/2013	\$136,448
CBCRA	Operating		CUX1 in Mammary Tumors	07/2008-06/2013	\$149,953
CIHR	Team Grant		CIHR Team in Cancer Progression and Metastasis	04/2006-03/2011	

PARK, Morag

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Role of Gab Family Signal Amplifiers in Tumorigenesis and Invasion	10/2010-09/2015	\$154,481
QCDM			Development of integrated tumor-microenvironmental classifiers for personalized therapy targeting	09/2011-08/2014	\$144,444
CIHR	SDRPS		Role of Crk Adapter Proteins in Cell Invasion and Metastasis	08/2008-07/2014	\$150,000
CCSRI	TFFNFPPG Team Grant	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	
CIHR	Operating		Mechanisms of oncogenic activation of the met RTK in human cancer	10/2010-09/2013	\$185,344
GQ	Operating	wHallett	Next Generation Predictive Signatures for Breast Cancer	09/2010-08/2013	
FRSQ	Operating		Tests pronostiques pour le cancer du sein basés sur l'immunohistochimie intégrant les composantes épithéliales et stromales	07/2010-06/2013	\$161,350
CIHR	CIHR Training	wHallett	Integrative Approaches to Human Health	07/2010-06/2013	

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

	Grant				
CCSRI	CBCRA Predictive Oncology Grant		Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative disease	04/2011-03/2013	\$159,985
FRSQ	Network Grant		Banque de tumeurs	04/2007-03/2012	\$50,000
CRS	Strategic Grant		Gene expression and phenotypic characterization of circulating tumor cells: Towards an understanding of the seeds of metastasis	01/2009-01/2012	\$149,999
NSERC	CHRP		Microfluidic detection system for profiling multiple cancer biomarkers in serum with ultrahigh sensitivity and specificity	04/2008-03/2011	\$15,900
CIHR	CIHR Team Grant	wSiegel	CIHR Team in Models of Cancer Progression and Metastasis	04/2006-03/2011	

PAUSE, Arnim

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR/TFRI	Oncometabol . Team Grant		Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
CRS	Operating		Metabolic role of the tumor suppressor HD-PTP in lung tumorigenesis	09/2011-08/2013	\$20,000
Myrovlytis Trust, UK	Operating		Functional Characterization of the Folliculin Tumor Suppressor Protein	07/2011-06/2013	\$77,500
CCSRI	Operating		Role of the inactive tyrosine phosphatase HD-PTP in cancer	07/2010-07/2013	\$138,000
CIHR	Operating		Investigating the mechanism of action of the von Hippel-Lindau tumor suppressor protein	09/2007-08/2012	\$143,800
KFC	Operating		Characterization of the Folliculin Tumor Suppressor	07/2010-07/2012	\$50,000
CRS	Operating		Role of the inactive tyrosine phosphatase HD-PTP in lung	09/2009-08/2011	\$40,000

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			cancer		
--	--	--	--------	--	--

PELLETIER, Jerry

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		RNA Helicases in Tumorigenesis	10/2011-09/2016	\$40,000
CIHR	Operating		Modelling Translation Initiation as Cancer Therapy	10/2010-09/2015	\$159,410
NCIC	Operating		Chemical Dissection of Translation Initiation	07/2009-06/2014	\$138,000
QCDM		wShore	Integrated Platform: Synthetic Lethality in Cancer Therapy	07/2010-07/2013	
CIHR	POP		Chemotherapeutic Agents for Inhibiting Protein Synthesis	09/2011-08/2012	\$53,333
MDEIE			L'Imagerie par la Microscopie à Force Atomique de l'Hélicase d'ARN eIF4A: Application à la Conception de Nouvelles Drogues (IMHA)	12/2008-11/2011	\$45,833
CIHR	Team Grant	wSonenberg	CIHR Team Grant in Memory	04/2006-03/2011	
CIHR	Operating		Linking Translation to Chemotherapy	04/2006-03/2011	\$35,333

SHORE, Gordon

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Bcl-2 family Proteins, Cell Death and the Endoplasmic Reticulum	10/2010-09/2015	\$261,747
GQ	Operating		Therapeutic Development Platform: Targeting Metabolism in Cancer Therapy	10/2010-09/2013	\$324,869
CQDM	Operating		Integrated Platform: Synthetic Lethality in Cancer	09/2010-08/2013	\$669,997

SIEGEL, Peter

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CCSRI	Research Grant		ShcA-dependent mechanisms driving breast cancer migration and invasion	07/2011-06/2014	\$73,758
CCSRI	TFFNFPPG Team Grant	wMuller	Preclinical models and therapeutic targets for	07/2009-06/2014	

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			metastatic breast disease		
GQ	Research Grant	wHallett	Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	
AICR	Research Grant		ErbB2/TGFbeta signaling pathway interactions in breast cancer	01/2011-12/2013	\$99,566
CRS	Operating		Defining Mechanisms by which CCN3 Promotes the Formation of Osteolytic Bone Metastases	09/2011-08/2013	\$20,000
NSERC	CHRP	coApp	Microfluidic detection system for profiling multiple cancer biomarkers in serum with ultrahigh sensitivity and specificity	04/2008-03/2011	\$15,900
CIHR	Team Grant		CIHR Team in Cancer Progression and Metastasis	04/2006-03/2011	\$227,886

SONENBERG, Nahum

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		The role of mTOR pathway in translational regulation of synaptic plasticity, memory formation and disease	10/2011-03/2016	\$49,909
CIHR/TFRI	Oncometabol . Team Grant		Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
CIHR	Operating		Mechanism of miRNA action in translation and mRNA decay	04/2009-03/2014	\$156,927
CIHR	Operating		Michael Smith Prize in Health Research	04/2009-03/2014	\$100,000
CRS	Operating		mTOR inhibition and translational control of pancreatic neuroendocrine tumours	09/2011-08/2013	\$20,000
CCSRI	Operating		Translational control in oncogenesis: Signaling to the translation initiation factor	07/2010-06/2013	\$142,500
Autism Speaks	Operating		Regulation of neuronal translation in Autism Spectrum Disorders	02/2011-01/2013	\$27,499
CIHR	Operating		Mechanisms of translation initiation and control in	10/2007-09/2012	\$239,913

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			eukaryotes		
CIHR	Team Grant	wCohen	CIHR Team 'HIV Pathogenesis'	10/2007-09/2012	\$120,450
NIH (USA)	Operating		Translational control by poly(A)-binding protein and its modulators (Paips)	07/2008-06/2012	\$198,685
NCIC	TFFNFPPG	wBell	Canadian Oncolytic Virus Consortium	07/2007-06/2012	\$188,080
CIHR	Catalyst Grant		The role of mTOR pathway in age-associated memory decline	04/2011-03/2012	\$37,500
Howard Hughes Medical Institute	Int. Research Scholars Program		Control of synaptic plasticity, learning and memory at the mRNA translation level	01/2007-12/2011	\$103,244
Brain Tumour Foundation of Canada	Operating		Role of DHX29 in the pathogenesis of brain cancers	07/2010-06/2011	\$12,480
CIHR	Team Grant		CIHR Team in Memory	04/2006-03/2011	\$58,623

ST-PIERRE, Julie

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		The role of the PGC-1 transcriptional coactivators in the regulation of breast cancer metabolism	10/2010-09/2015	\$131,088
CIHR/TFRI	Oncometabol . Team Grant		Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	
GQ	Concours santé-volet translationel	wShore	Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer	09/2010-08/2013	
FRSQ	Fond d'établissement		The role of PGC-1 alpha in the regulation of cancer metabolism	07/2010-06/2013	\$15,000
MCC	McGill-Weizmann partnership		Metabolism and DNA damage response	04/2011-03/2013	\$60,000
GQ	Pilot project		Metabolomics of ERBB2-induced breast tumors	10/2010-09/2012	\$100,000
CFI	Leaders		The role of the peroxisome	06/2009-	\$72,916

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

	Opportunity Fund		proliferator activated receptor gamma coactivators (PGCs) in the regulation of cancer metabolism	05/2011	
--	------------------	--	--	---------	--

TEODORO, Jose

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Tumour suppressor mediated mechanisms of angiogenesis inhibition	10/2011-09/2014	\$31,877
CIHR	Operating		Mechanism of Action of the Adenovirus Death Protein E4orf4	04/2009-03/2014	\$164,471
NSERC	Discovery Grant		Biology of Circoviruses	04/2009-03/2014	\$40,000
CIHR	Operating		Role of the Anaphase Promoting Complex in Cancer and Viral Infection	04/2008-03/2013	\$116,478
Colon Cancer Canada	Operating		Role of the GOS2 Gene in progression of colorectal cancer	12/2011-11/2012	\$4,166
CIHR	Operating		Characterization of novel mechanisms of angiogenesis inhibition	04/2008-03/2011	\$33,729

TREMBLAY, Michel

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		PTP-1b as a target in human cancer	04/2011-03/2016	\$113,991
CCSRI	Operating		Understanding and targeting TC-PTP in immune diseases and cancer	07/2011-06/2014	\$56,044
CIHR/TFRI	Oncometabol. Team Grant		Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	\$638,550
QBCF	Operating		Role of the protein tyrosine phosphatase PRL-2 in breast cancer development and metastasis	01/2009-06/2014	\$149,445
CRS	Pancreatic Cancer Research		Linking cancer anorexia-cachexia syndrome, resting energy expenditure and chronic	07/2010-06/2013	\$20,000

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

	Program		inflammation state in patients with pancreatic cancer through cellular metabolic mechanisms and their unique metastatic control		
DOD	CDMRP		Characterization of the oncogenic potential of protein tyrosine phosphatase 1B in prostate cancer	03/2009-02/2012	\$153,194
CIHR	POP		Discovery and uses of a new class of small molecule inhibitors of tyrosine phosphatases	10/2010-09/2011	\$52,950
CIHR	Operating		PTP1b as a target in human diseases: obesity, diabetes and cancer	04/2006-03/2011	\$38,078

YAMANAKA, Yojiro

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Cell polarity and generation of the first distinct lineages in the mouse embryo	04/2011-03/2016	\$111,681
CFI	Leaders Opportunity Fund		Epithelial morphogenesis in early development and cancer	10/2010-09/2011	\$225,000
CIHR	Operating – Bridge Funding		Cell polarity and generation of the first distinct lineages in the mouse embryo	10/2010-09/2011	\$75,000
McGill Faculty Med	NI Start-up		New investigator start-up funds	07/2009-06/2011	\$42,500

YANG, Xiang-Jiao

Agency	Type	Grant #	Title	Funding Period	Amount 2011
CIHR	Operating		Role of a kinase-deacetylase-MEF2 signaling axis in normal and oncogenic cellular programs	10/2009-09/2014	\$135,477
CIHR	CIHR-China Collaboration Initiative		Role of epigenetic regulators in mediating anti-aging effects of PTHrP	01/2010-12/2012	\$50,000
NCIC	Operating		Functional analysis of MOZ and MORF histone acetyltransferase complexes	07/2007-06/2012	\$136,253
NSERC	Discovery Grant		Roles of a recurrent phospho-sumoyl switch in coordinated	04/2007-03/2012	\$30,000

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

			transcriptional control		
--	--	--	-------------------------	--	--

ZANNIS-HADJOPOULOS, Maria

Agency	Type	Grant #	Title	Funding Period	Amount 2011
NSERC	Operating		Functional synergy between the DNA topology and DNA repair machineries during the initiation of DNA replication	07/2011-06/2016	\$15,000
CRS	Operating		The role of Ku in breast tumorigenesis: Implications for therapy	09/2010-08/2012	\$20,000

ZOGOPOULOS, George

Agency	Type	Grant #	Title	Funding Period	Amount 2011
MUHC RI	NI Start-up Operating		Start-up Operating Funds	08/2011-08/2014	\$31,250
MCC	NI Start-up Operating		Start-up Operating Funds	08/2011-08/2014	\$4,166
MUHC RI	NI Start-up Equipment		Start-up Equipment Fund	01/2011-12/2011	\$50,000

*Note: For group grants on which the PI is part of the Goodman Cancer Research Centre (GCRC), the full amount awarded for 2011 has been attributed to the main PI applicant for reporting purposes. For group grants on which the PI is **not** from the GCRC, the individual researcher's share for 2011 is indicated. Dollar amounts indicated are for the actual number of funded months in 2011. If the funding period spans across only 3 months in 2011, the amount indicated represents 3 months of funding.*

Appendix IV – Publications

Note: Number of Publications: 102 (including book chapters and reviews)

BEAUCHEMIN, Nicole, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Beauchemin%20N.%20%5bAuthor%5d%20McGill>

- Fiset, A., Xu, E.*, Bergeron, S., Marette, A., Pelletier, G., Siminovitch, K.L., Olivier, M., **Beauchemin, N.** and R.L. Faure. Compartmentalized Cdk2 is connected with SHP-1 and β -catenin and regulates insulin internalization. *Cell Signaling*, 23(5):911-9 (2011).
- Gerstel, D., Wegwitz, F., Jannasch, K., Ludewig, P., Scheike, K., Alves, F., **Beauchemin, N.**, Deppert, W., Wagener, C. and Horst, A.K. CEACAM1 creates a pro-angiogenic micro-environment that supports tumor vessel maturation. *Oncogene*, 30(41):4275-88. (2011).
- Meunier, C.*, Kwan, T., Turbide, C.*, **Beauchemin N.*** and Gros, P.*. Genetic Control of Susceptibility to Carcinogen-Induced Colorectal Cancer in Mice: The *Ccs3* and *Ccs5* Loci Regulate Different Aspects of Tumorigenesis. *Cell Cycle*, 10 (11) 1739-49 (2011). *co-senior author.
- Beauchemin, N.** The Colorectal Tumor Microenvironment: The Next Decade. *Cancer Microenvironment* 4: 181-5 (2011).
- Lu, S.X., Kappel, L.W., Charbonneau-Allard, A.-M., Atallah, R., Holland, A.M., Turbide, C., Hubbard, V.M., Rotolo, J.A., Smith, J.M., Suh, D., King, C., Rao, U.K., Yim, N., Bautista, J.L., Jenq, R.R., Penack, O., Na, I.-K., Liu, C., Murphy, G., Alpdogan, S.O., Blumberg, R.S., Macian, F., Holmes, K.V., **Beauchemin, N.***, van den Brink, M.R.M.*. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. *PLoSOne*. 6 (7), e21611 (2011). *co-senior author.
- LeBlanc, S.*, Nouvion, A.L.*, Arabzadeh, A., Benlolo, S., Breton, V., Turbide, C. and **Beauchemin, N.** CEACAM1 deficiency delays wound healing. *Wound Repair and Regeneration* 19(6):745-52 (2011). * contributed equally to the work.
- Chen, Z., Chen, L., Baker, K., Olszak, T., Zeissig, S., Mandelboim, O., **Beauchemin, N.**, Lanier, L.L. and Blumberg, R.S. CEACAM1 dampens anti-tumor immunity via bidirectional down-regulation of NKG2D ligand expression on tumor cells and NKG2D function on NK cells. *J. Exp. Med.* 208(13):2633-40 (2011).

Book Chapters:

- Sigmundsson, K., **Beauchemin, N.**, Lengqvist, J. and Öbrink, B. Determination of binding kinetics between proteins with multiple nonidentical binding sites by SPR flow cell biosensor technology. Chapter 3, *Biosensors for Health, Environment and Biosecurity / Book 1*, editors: In Tech, 35-58 (2011).

BOUCHARD, Maxime, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bouchard%20M%20%5bAuthor%5d%20McGill>

- Boualia, S.K., Gaitan, Y., Murawski, I., Nadon, R., Gupta, I.R. and **Bouchard M.** (2011). Vesicoureteral Reflux and Other CAKUT-like Malformations in Mice Compound Heterozygous for Pax2 and Emx2. PLoS One 6(6):e21529. (Impact factor 4.4)
- Chia, I.*, Grote, D.*, Marcotte, M., Batourina, E., Mendelsohn, C.# and **Bouchard M.#** (2011) Nephric duct insertion is a crucial step in urinary tract maturation regulated by a Gata3-Raldh2-Ret molecular network in mice. Development 138(10):2089-97. (Impact factor: 6.9)
*Equal contributors, # co-corresponding authors.

BRANTON, Philip, Dr.

URL:

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=branton+pe%5BAuthor%5D%22>

- Branton, P.E.** and R. C. Marcellus. 2011. Adenoviruses, In "Fundamentals of Molecular Virology" (2nd edition). Ed. N. Acheson. John Wiley and Sons, New York, NY. pp. 274-284.
- Zhang, Z., M. Z. Mui, F. Chan, D.E. Roopchand, R.C. Marcellus, P. Blanchette, S. Li, A.M. Berghuis and **P.E. Branton**. 2011. Genetic analysis of B55 α /Cdc55 PP2A subunits: Association with the adenovirus E4orf4 protein. J. Virol. 85, 286-295.
- Cheng, C.Y., T. Gilson, F. Dallaire, G. Ketner, **P.E. Branton** and P. Blanchette. 2011. The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J. Virol. 85, 765-775.
- Schreiner, S., P. Wimmer, P. Groitl, A. Chan, P. Blanchette, **P.E. Branton**, and T. Dobner. 2011. Adenovirus type 5 early region 1B 55K oncoprotein dependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells. J. Virol. 85, 8752-8765.

DUCHAINE, Thomas, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Duchaine%20T%20%5bAuthor%5d>

- Caroline Thivierge*, Neetha Makil*, Mathieu Flamand, James Wohlschlegel, Jessica J. Vasale, Craig C. Mello, Darryl Conte Jr. and **Thomas F. Duchaine** (Corresponding Author). Tudor domain ERI-5 tethers an RNA-dependent RNA polymerase to DCR-1 to potentiate endoRNAi. Nat Struct Mol Biol. 2011 Dec 18;19(1):90-7.
- Marc R. Fabian, Maja K. Cieplak, Masahiro Morita, Jonathan Green, Tadashi Yamamoto, **Thomas F. Duchaine** and Nahum Sonenberg. GW182 orchestrates microRNA-mediated deadenylation via a conserved pair of CCR4-NOT interacting motifs. Nat Struct Mol Biol. 2011 Oct 7;18(11):1211-7.

Book chapters:

- Edlyn Wu & **Thomas F. Duchaine (Corresponding Author)** 'Cell-free miRNA-mediated translation repression in *C. elegans*'. *Methods in Molecular Biology* 2011; 725: 219-232.

GALLOUZI, Imed, Dr.

URL:

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=gallouzi+i%5BAuthor%5D>

- von Roretz, C., Macri, A.M., and **Gallouzi, I.E.** “Transportin 2 regulates apoptosis through the RNA-binding protein HuR.” *J. Biol. Chem.*; 286(29):25983-91 (2011).
- Dauletbaev, N., Eklove, D., Mawji, N., Iskandar, M., Di Marco, S., **Gallouzi, I.E.**, Lands, L.C. Both MKP-1 dependent and independent inhibition of p38 MAPK are required for efficient pharmacological down-regulation of IL-8. *J. Biol. Chem.*; 286(18):15998-6007 (2011).

GIGUERE, Vincent, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giguere%20V%22\[Author\]%20Mcgill](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giguere%20V%22[Author]%20Mcgill)

- Liu, X., Nugoli, M., Laferrière, J., Saleh, S.I., Rodrigue-Gervais, I.G., Saleh, M., Park, M., Hallett, M., Muller, W.J. and **Giguère, V.** (2011) Stromal RAR β promotes mammary gland tumorigenesis. *Proc. Natl. Acad. Sci. USA* 108:774-779
- Eichner, L.J. and **Giguère, V.** (2011) Estrogen related-receptors (ERRs): a new dawn in transcriptional control of mitochondrial gene networks. *Mitochondrion* 11:544-552.
- Deblois, G. and **Giguère, V.** (2011) Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. *BBA Mol. Med.* 1812:1032-1040.
- Marquis, J.M., Kapoustina, O., Langlais, D., Ruddy, R., Dufour, C.R., Kim, B.-H., MacMicking, J.D., **Giguère, V.** and Gros, P. (2011) IRF8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis. *PLoS Genetics* 7:e1002097.
- Dufour, C.R., Pham, N.H.H., Levasseur, M.-P., Eichner, L.J., Wilson, B.J., Charest-Marcotte, A., Duguay, D., Poirier-Héon, J.F., Cermakian, N. and **Giguère, V.** (2011) Genomic convergence between ERR α , PROX1 and BMAL1 in the control of metabolic clock outputs. *PLoS Genetics* 7:e1002143.
- Goulet, B., Kennette, W., Ablack, A., Postenka, C.O., Hague, M.N., Mymryk, J.S., Tuck, A.B., **Giguère, V.**, Chambers, A.F. and Lewis, J.D. (2011) Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. *Laboratory Investigation* 91:1181-1187.
- *Featured on the cover.
- Michalek, R.D., Gerriets, V.A., Nichols, A.G., Inoue, M., Kazmin, D., Chang, C.-y., Dwyer, M.A., Nelson, E.R., Pollizzi, K.N., Ilkayeva, O., **Giguère, V.**, Zuercher, W.J., Powell, J.D., Shinohara, M.L., McDonnell, D.P. and Rathmell, J. (2011) Estrogen-related receptor α is a metabolic regulator of effector T cell activation and differentiation. *Proc. Natl. Acad. Sci. USA* 108:18348-18353.

GROS, Philippe, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gros%20P%22%20%5bAuthor%5d%20McGill>

- Hambleton, S. Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S., Azevedo, J., Fortin, Haniffa, M., Ceron-Gutierrez, L., Bacon, CM., Menon, G., Trouillet, C., McDonald, D., Carey, P., Ginhoux, F., Alsina, L., Zumwalt, T., Kong, X., Kumararatne, D., Butler, K., Hubeau, M., Feinberg, J., Al-Muhsen, S., Cant, A., Abel, L., Chaussabel, D., Doffinger, R., Talesnik, E., Grumach, A., Duarte, A., Abarca, K., Moraes-Vasconcelos, D., Burk, D., Berghuis, A., Geissmann, F., Collin, M., Casanova, JL. and **Gros, P.** “IRF8 mutations and human dendritic cell immunodeficiency” *N Engl J Med.* 365(2):127-38, 2011.
- Radovanovic, I., Mullick, A. and **Gros, P.** “Genetic control of susceptibility to infection with *Candida albicans* in mice” *PLoS ONE* 6(4): e18957, 2011
- Kibar, Z., Salem, S., Bosoi, CM., Pawels, E., De Marco, P., Merello, E., Bassuk, AG, Capra, V and **Gros, P.** “Contribution of VANG12 mutations to isolated neural tube defects” *Clin. Genetics.* 80(1):76-82, 2011.
- Iliescu, A., Gravel, M., Horth, C., Kibar, Z. and **Gros, P.** “Loss of membrane targeting of Vangl proteins causes neural tube defects” *Biochemistry.* 50(5):795-804, 2011.
- Yoon, H., **Gros, P.**, and Heffron, F. “A qPCR-based competitive index for high-throughput screening of *Salmonella* virulence factors” *Infect Immun.* 79(1):360-368, 2011.
- Iliescu, A., Gravel, M., Horth, C., Apuzzo, S. and **Gros, P.** “Transmembrane topology of the mammalian planar cell polarity protein Vangl1” *Biochemistry.* 50(12):2274-82, 2011.
- Min-Oo, G. and **Gros, P.** “Genetic analysis in mice identify cysteamine and artemisinin as a novel combination therapy for malaria”. *Mamm. Genome* 22(7-8):486-94, 2011.
- Marquis, JF., Kapoustina, O., Langlais, D., Ruddy, R., Dufour, CR, Giguere, V. and **Gros, P.** “Interferon Regulatory Factor 8 regulates pathways for antigen processing and antigen presentation in myeloid cells” *PLoS Genet* 7(6): e1002097, 2011.
- Guyot, MC., Bosoi, CM., Reynolds, A., Milette, R., Drapeau, P., Justice, M., **Gros, P.** and Kibar, Z. “A novel hypomorphic “Looptail” allele at the planar cell polarity gene Vangl2” *Dev. Dynamics* 240(4):839-849, 2011.
- Berghout, J., Higgins, S., Sakuntabhai, A., Kain, K. and **Gros, P.** “Genetic diversity in human erythrocytic pyruvate kinase (PKLR)” *Genes Immun.* 2011 Aug 11. [Epub ahead of print]
- Laroque, A., Min-Oo, G., Tam, M., Stevenson, MM. and **Gros, P.** “Genetic control of susceptibility to blood stage malaria in inbred mouse strains: Effect of the Char1 locus” *Genes Immun.* 2011 Oct 6. [Epub ahead of print]
- Seo, JH., Ziber, Y., Babayeva, S., Liu, J., Kiriakopoulos, P., De Marco, P., Merello, E., Capra, V., **Gros, P.** and Torban E. “Mutations in the planar cell polarity gene fuzzy are associated with neural tube defects in humans “ *Hum. Mol. Genet* 20(22):4324-33, 2011.
- Meunier, C., Kwan, T., Turbide, C., Beauchemin, N. and **Gros, P.** “Genetic Control of Susceptibility to Carcinogen-Induced Colorectal Cancer in Mice: The Ccs3 and Ccs5 Loci Regulate Different Aspects of Tumorigenesis” *Cell Cycle* 10: 1739-1749, 2011.
- Fortier, A., Faucher, SP., Diallo, K. and **Gros, P.** “Global cellular changes induced by *Legionella pneumophila* infection of bone marrow-derived macrophages” *Immunobiol.* 216(12):1274-85, 2011

HALLETT, Michael, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hallett%20M%22%20%5BAuthor%5D%20cancer>

- Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJ, Bertos N, **Hallett MT**, Park M, Juncker D. (2011) Antibody colocalization microarray: A scalable technology for multiplex protein analysis in complex samples. *Mol Cell Proteomics*. 2011 Dec 14. [Epub ahead of print]
- Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ, Cory S, **Hallett MT**, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G, Lawler SE, Chiocca EA, Leone G, Ostrowski MC. (2011) Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. *Nat Cell Biol*. 2011 Dec 18;14(2):159-67. doi: 10.1038/ncb2396
- Borghol N, Suderman M, McArdle W, Racine A, **Hallett MT**, Pembrey M, Hertzman C, Power C, Szyf M (2011) Associations with early-life socio-economic position in adult DNA methylation. *Int. J. Epidemiol*. doi: 10.1093/ije/dyr147
- Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, **Hallett MT**, Siegel PM (2011). Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. *Oncogene*. 17;30(11):1318-28.
- Liu X, Nugoli M, Laferrière J, Saleh SM, Rodrigue-Gervais IG, Park M, **Hallett MT**, Muller WJ, Giguère V (2011) Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. *Proc Natl Acad Sci U S A*. 11;108(2):774-9.
- Stefanska B, Huang J, Bhattacharyya B, Suderman M, **Hallett MT**, Han ZG, Szyf M. (2011) Definition of the landscape of promoter DNA hypomethylation in liver cancer. *Cancer Res*.17(17):5891-903.
- Gosline, SJC, Nascimento M, McCall, L, Zilberstein, D, Thomas, DY, Matlashewski, G and **Hallett MT** (2011) Intracellular eukaryotic parasites have a distinct unfolded protein response, *PLoS One*. 29;6(4):e19118.
- Sansregret, L., Livingstone J, Vadnais C, Kwiatkowski N, Awan A, Cadieux C, Leduy L, **Hallett MT**, Nepveu (2011) CUX1 causes chromosomal instability by promoting bipolar divisions after mitotic failure. *Proceedings of the National Academy of Sciences of the USA*, 108(5):1949-1954. 2011.
- McGowan P, Suderman M, Sasaki A, Huang TCT, **Hallett MT**, Meaney MJ, Szyf M (2011) Broad epigenetic signature of maternal care in the brain of adult offspring. *PLoS One* 6(2):e14739
- Liu X, Nugoli M, Laferrière J, Saleh SM, Rodrigue-Gervais IG, Park M, **Hallett MT**, Muller WJ, Giguère V. (2011) Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. *Proc Natl Acad Sci U S A*. 108(2):774-9.

JONES, Russell, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jones%20RG%22%5BAuthor%5D>

- MacIver, N., Blagih, J., Saucillo, D.C., Tonelli, L., Griss, T., Rathmell, J.C., and **Jones, R.G.** (2011). The Liver Kinase B-1 (LKB1) is a central regulator of T cell development, activation, and metabolism. *J. Immunol.* 187(8):4187-98.
- Zaugg, K., Yao, Y., Reilly, P.T., Kannan, K., Kiarash, R., Mason, J., Huang, P., Sawyer, S.K., Fuerth, B., Faubert, B., Kalliomaki, T., Elia, A., Luo, X., Nadeem, V., Bungard, D., Yalavarthi, S., Gowney, J.D., Wakeham, A., Moolani, Y., Silvester, J., Ten, A.Y., Bakker, W., Tsuchihara, K., Berger, S.L., Hill, R.P., **Jones, R.G.**, Tsao, M., Robinson, M.O., Thompson, C.B., Pan, J.G., and Mak, T.W. (2011). Carnitine Palmitoyltransferase 1C Promotes Cell Survival and Tumor Growth under Conditions of Metabolic Stress. *Genes Dev.* 25(10):1041-51.

McCAFFREY, Luke, Dr.

URL:

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=mccaffrey+!%5BAuthor%5D>

- McCaffrey L.**, Macara I.G. (2011) Epithelial organization, cell polarity, and tumorigenesis. *Trends Cell Biol.* 2011 Dec;21(12):727-35.1.

MULLER, William, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Muller%20WJ%22%5bAuthor%5d%20McGill>

- Liu, X., Nugoli, M., Laferriere, J., Saleh, S.M., Rodrigue-Gervais, I.G., Saleh, M., Park, M., Hallett, M.T., **Muller, W.J.** and Giguere, V. (2011). Stromal retinoic acid receptor β promotes mammary gland tumorigenesis. *PNAS* 108, 774-779.
- Raven, J.F., Williams, V., Wang, S., Tremblay, M.L., **Muller, W.J.**, Durbin, J.E., and Koromilas, A.E. (2011). Sta1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. *Cell Cycle* 10, 794-804.
- Hassan, S., Buchanan, M., Jahan, K., Aguilar-Macecha, A, Gaboury, L, **Muller, W.J.**, Alsawafi, Y., Mourskaia, Siegel, P.M., Salvucci, O, and Basik, M. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. *Int. J. Cancer* 129, 225-232
- Cheng, X., Xia, W., Yang, J.W., Hsu, J.L., Chou, C.K., Sun, H.L., Wyszomierski, S.L., Mills, G.B., **Muller, W.J.**, Yu, D., and Hung, M-C. (2011) Activation of p21 (CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. *BBRC* (in press).
- Marcotte, R., Smith, H, Sanguin-Gendreau, V., McDonough, R., and **Muller, W.J.** (2011). Mammary epithelial disruption of c-Src impairs cell cycle progression and tumorigenesis. *PNAS*

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

- Lahlou, H. and **Muller, W.J.** (2011) β 1 integrin signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. *Breast Cancer Research* 229, 13.
- Ahmad1, I., Patel1, R. Singh, L.B. Nixon, C., Seywright, M., Barnetson R. J., Brunton, V, **Muller, W. J.**, Edwards, J., Sansom, O. J. Leung, H. J (2011). HER2 overcomes PTEN (loss) induced Senescence to cause Aggressive Prostate Cancer. *PNAS* 108. 16392-16397
- Mounir, Z., Krishnamoorthy, J. L., Wang, S., Papadopoulou, B., Campbell, S., **Muller, W.J.**, Hatzoglou, M., and Koromilas, A. E. (2011). Akt determines cell fate through inhibition of PERK-eIF2a phosphorylation pathway. *Sci. Signaling* 4, 62.

NEPVEU, Alain, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nepveu%20A%22\[Author\]%20McGill](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nepveu%20A%22[Author]%20McGill)

- Sansregret, L., J. Livingstone, C. Vadnais, N. Kwiatkowski, A. Awan, C. Cadieux, L. Leduy, M. Hallett, and **A. Nepveu**. CUX1 causes chromosomal instability by promoting bipolar divisions after mitotic failure. *Proceedings of the National Academy of Sciences of the USA*, 108(5):1949-1954. 2011.
- Sansregret, L., and **Nepveu, A.** Gene Signatures of Genomic Instability As Prognostic Tools for Breast Cancer. *Future Oncology*, 7(5):591-594. 2011.
- Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, **Nepveu A**, Koike K: MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. *Nature communications*, 2:338. 2011.

Book chapters:

- Harada, R. and **A. Nepveu**. Chromatin Affinity Purification. Ales Vancura (ed.), *Transcriptional Regulation: Methods and Protocols*, *Methods in Molecular Biology*, vol. 809, 809, 237-253. 2011.

PARK, Morag, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Park%20M%22%5bAuthor%5d%20McGill>

- Liu X., Nugoli M., Laferrière J*, Saleh SM, Rodrigue-Gervais IG, Saleh M., **Park M.**, Hallett M., Muller W., Giguère V. Stromal retinoic acid receptor β promotes mammary gland tumorigenesis. *Proc. Natl. Acad. Sci. USA*. 2011 Jan 11; 108(2):774-9.
- Parachoniak CA, Lui Y, Abella JV, Keen JH and **Park M.** GGA3 Functions as a Switch to Promote Met Receptor Recycling, Essential for Sustained ERK and Cell Migration. *Developmental Cell*. 2011 Jun 14; 20(6):751-63.
- Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SWY, McGoogan KE, Aslanidi GV, **Park M.**, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. *Gene Therapy*. Epub 21 July 2011; doi: 10.1038/gt.2011.105.

- Bertos NR, **Park M**. Breast cancer - one term, many entities? *J Clin Invest*. 2011 Oct 3;121(10): 3789-96. Epub 2011 Oct 3. Review.
- Sangwan V, Abella J, Lai A, Bertos N, Stuibler M, Tremblay ML, **Park M**. Protein tyrosine phosphatase PTP1B modulates early endosome fusion and trafficking of Met and EGF receptor tyrosine kinases. 2011 Dec 30;286(52):45000-13. Epub 2011 Nov 1
- Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJC., Bertos N, Hallett M, **Park M**, Juncker D. Antibody Colocalization Microarray: A Scalable Technology for Multiplex Protein Analysis in Complex Samples. *Molecular and Cellular Proteomics*. mcp.M111.011460. First Published on December 14, 2011, doi:10.1074/mcp.M111.011460.

PELLETIER, Jerry, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=Pelletier%2C%20Jerry\[Full%20Author%20Name\]](http://www.ncbi.nlm.nih.gov/pubmed?term=Pelletier%2C%20Jerry[Full%20Author%20Name])

- Ravindar, K., Reddy, M.S., Lindqvist, L., **Pelletier, J.**, and Deslongchamps, P. (2011). Synthesis of the antiproliferative agent hippuristanol and its analogues via Suárez cyclizations and Hg(II)-catalyzed spiroketalizations. *J. Org. Chem.* 76: 1269-1284.
- Cencic, R., Hall, D.R., Robert, F., Du, Y., Min, J., Li, L., Qui, M., Lewis, I., Kurtkaya, S., Dingleline, R., Fu, H., Kozakov, D., Vadja, S., and **Pelletier, J.** (2011). Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. *PNAS* 108: 1046-1051
- Takacs, J.E., Neary, T.B., Ingolia, N.T., Martin-Marcos, P., Weissman, J.S., **Pelletier, J.**, Hinnebusch, A.G., and Lorsch, J.R (2011). Identification of compounds that decrease the fidelity of start codon recognition by the eukaryotic translational machinery. *RNA* 17: 439-452.
- Huang, S-X., Zhao, L-X., Jiang, C-J., Duan, Y., Roberts, F., **Pelletier, J.**, and Shen, B. (2011) Cycloheximide and congeners, inhibitors of eukaryotic protein synthesis, from *Streptomyces* spp. YIM56141 and 56132. *J. Antibiotics*. 64: 163-166.
- Warr, M.R., Mills, J.R., Nguyen, M., Lemaire-Ewing, S., Baardnsnes, J., Sun, K.L.W., Malina, A., Young, J.C., Jeyaraju, D.V., O'Connor-McCourt, M., Pellegrini, L., **Pelletier, J.**, and Shore, G. (2011). Mitochondrial-dependent N-terminal Processing of Outer Membrane Mcl-1 Removes an Essential Mule/Las1 Binding Site. *J. Biol. Chem.* 286: 25098-25107.
- Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingleline R, Fu H, Vajda S, Talbot PJ, **Pelletier J.** (2011) Blocking eIF4E:eIF4G interaction as a strategy to impair coronavirus replication. *J. Virol.* 85: 6381-6389.
- Dauber B, **Pelletier J**, Smiley JR. (2011). The Herpes Simplex Virus 1 vhs protein enhances translation of viral true late mRNAs and virus production in a cell type-dependent manner. *J. Virol.* 85: 5363-5373.
- Konicek, B.W., Stephens, J.R., McNulty, A.M., Robichaud, N., Peery, R.B., Dumstorf, C.A., Dowless, M.S., Iversen, P.W., Parsons, S., Ellis, K.E., McCann, D.J., **Pelletier, J.**, Furic, L., Yingling, J.M., Stancato, J.F., Sonenberg, N., and Graff, J.R. (2011). Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastasis. *Cancer Res.* 71: 1849-1857.

- Wahba, A.S., Azizi, F., Deleavey, G.F., Brown, C., Robert, F., Carrier, M., Kalota, A., Gewirtz, A.M., **Pelletier, J.**, Hudson, R.H.E., and Damha, M.J. (2011). Phenylpyrrolocytosine as an unobtrusive base modification for monitoring activity and cellular trafficking of siRNA. *ACS Chem. Biol.* 6: 912-919.
- Schatz, J.H., Oricchio, E., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Zelenetz, A., Teruya-Feldstein, J., **Pelletier, J.**, and Wendel, H.-G. (2011) Therapeutic inhibition of cap-dependent translation coordinately blocks redundant AKT and PIM kinase signals in lymphoma. *J. Exp. Med.* 208: 1799-1807.
- Kozakov, D., Hall, D.R., Chuang, G.-Y., Cencic, R., Brenke, R., Beglov, D., **Pelletier, J.**, Whitty, A., and Vadja, S. (2011) Hot spot conservation and druggable sites in protein-protein interfaces. *PNAS.* 108: 13528-13533.
- Fred, R.G., Sandberg, M., **Pelletier, J.**, and Welsh, N. (2011). The human insulin mRNA is partly translated via a cap-and eIF4A-independent mechanism. *Biochem Biophys Res Commun.* 12: 693-698.

SHORE, Gordon, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shore%20GC%22%5BAuthor%5D%20McGill>

- Wang B, Nguyen M, Chang NC, **Shore GC**. Fis1, Bap31 and the kiss of death between mitochondria and endoplasmic reticulum. *EMBO J.* 2011 Feb 2;30(3):451-2.
- Warr MR, Mills JR, Nguyen M, Lemaire-Ewing S, Baardsnes J, L I W Sun K, Malina A, Young JC, Jeyaraju DV, O'Connor-McCourt M, Pellegrini L, Pelletier J, **Shore GC**. Mitochondrial-dependent N-terminal processing of outer membrane Mcl-1 removes an essential mule/las1 binding site. *J Biol Chem.* 2011 May 25. [Epub ahead of print]
- Acoca S, Cui Q, **Shore GC**, Purisima EO. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. *Proteins.* 2011 May 16. doi: 10.1002/prot.23083. [Epub ahead of print]
- Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, Lazrove E, Nabili P, Flaherty B, Graham M, Chen Y, Messerli SM, Mariggio MA, Rahner C, McNay E, **Shore GC**, Smith PJ, Hardwick JM, Jonas EA. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. *Nat Cell Biol.* 2011 Sep 18;13(10):1224-33. doi: 10.1038/ncb2330.
- Heath-Engel HM, Wang B, **Shore GC**. Bcl2 at the endoplasmic reticulum protects against a Bax/Bak-independent paraptosis-like cell death pathway initiated via p20Bap31. *Biochim Biophys Acta.* 2012 Feb;1823(2):335-47. Epub 2011 Dec 8.

SIEGEL, Peter, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Siegel%20PM%20%5bAuthor%5d>

- J. Li, A. Karaplis, D.C. Huang, **P.M. Siegel**, A. Camirand, X.F. Yang, W.J. Muller and R. Kremer. (2011). PTHrP drives breast tumor initiation, progression and metastasis in mice, and is a potential target for therapy. *J. Clin. Invest.* 121(12):4655-4669.

- M. Labelle-Côté, J. Dusseault, S. Ismaïl, A. Picard-Cloutier, **P.M. Siegel** and L. Larose (2011). Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth rate in vivo. *BMC Cancer*. 11:443.
- V. Ouellet, K. Tiedemann, A. Mourskaia, J.E. Fong, D. Tran-Thanh, E. Amir, M. Clemons, B. Perbal, S.V. Komarova and **P.M. Siegel** (2011). CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. *Am. J Path.* 178(5):2377-2388.
- S. Tabariès, Z. Dong, M.G. Annis, A. Omeroglu, F. Pepin, V. Ouellet, C. Russo, M. Hassanain, P. Metrakos, Z. Diaz, M. Basik, N. Bertos, M. Park, C. Guettier, R. Adam, M. Hallett and **P.M. Siegel** (2011). Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. *Oncogene*. 30(11):1318-1328.
- Y. He, J.J. Northey, M. Primeau, R.D. Machado, R. Trembath, **P.M. Siegel** and N. Lamarche-Vane (2011). CdGAP is required for Transforming Growth Factor β - and Neu/ErbB-2-induced breast cancer cell motility and invasion. *Oncogene*. 30(9):1032-1045.
- S. Hassan, M. Buchanan, L. Gaboury, W. Muller, A. Alsawafi, A. Mourskaia, **P. Siegel** and M. Basik. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. *Int. J Cancer*. 129(1):225-232.

SONENBERG, Nahum, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Sonenberg%20N.%20%5bAuthor%5d%20McGill>

- Alvarez-Saavedra, M., Antoun, G., Yanagiya, A., Oliva-Hernandez, R., Cornejo-Palma, D., Perez-Iratxeta, C., **Sonenberg, N.**, and Cheng, H-Y, M. (2011) miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. *Hum Mol Genet* 20(4), 731-751.
- Konicek, B.W., Stephens, J.R., McNulty, A.M., Robichaud, N., Peery, R.B., Dumstorf, C.A., Dowless, M.S., Iversen, P.W., Parsons, S., Ellis, K.E., McCann, D.J., Pelletier, J., Furic, L., Yingling, J.M., Stancata, L.F., **Sonenberg, N.**, and Graff, J.R. (2011) Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. *Cancer Res* 71(5), 1849-1857.
- Jaramillo, M., Gomez, M.A., Larsson, O., Shio, M.T., Topisirovic, I., Contreras, I., Luxenburg, R., Rosenfeld, A., Colina, R., McMaster, R.W., Olivier, M., Costa-Mattioli, M., and **Sonenberg, N.** (2011) Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. *Cell Host Microbe* 9(4), 331-341.
- Frank, F., Fabian, M.R., Stepinski, J., Jemielity, J., Darzynkiewicz, E., **Sonenberg, N.**, and Nagar, B. (2011) Structural analysis of 5'-mRNA-cap interactions with the human AGO2 MID domain. *EMBO Rep* 12(5), 415-420.
- Larsson, O., **Sonenberg, N.**, and Nadon, R. (2011) anota: analysis of differential translation in genome wide studies. *Bioinformatics* 27(10), 1440-1441.

- Burke, J.D., **Sonenberg, N.**, Plataniias, L.C., and Fish, E.N. (2011) Antiviral effects of interferon- β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3. *Antiviral Therapy* 16(4), 577-584.
- Elfakess, R., Sinvani, H., Haimov, O., Svitkin, Y., **Sonenberg, N.**, and Dikstein, R. (2011) Unique translation initiation of mRNAs-containing TISU element. *Nucleic Acids Res* 39(17), 7598-7609.
- Chartier-Harlin, M.C., Dachsel, J.C., Vilariño-Güell, C., Lincoln, S.J., Leprêtre, F., Hulihan, M.M., Kachergus, J., Milnerwood, A.J., Tapia, L., Song, M.S., Le Rhun, E., Mutez, E., Larvor, L., Duflot, A., Vanbesien-Mailliot, C., Kreisler, A., Ross, O.A., Nishioka, K., Soto-Ortolaza, A.I., Cobb, S.A., Melrose, H.L., Behrouz, B., Keeling, B.H., Bacon, J.A., Hentati, E., Williams, L., Yanagiya, A., **Sonenberg, N.**, Lockhart, P.J., Zubair, A.C., Uitti, R.J., Aasly, J.O., Krygowska-Wajs, A., Opala, G., Wszolek, Z.K., Frigerio, R., Maraganore, D.M., Gosal, D., Lynch, T., Hutchinson, M., Bentivoglio, A.R., Valente, E.M., Nichols, W.C., Pankratz, N., Foroud, T., Gibson, R.A., Hentati, F., Dickson, D.W., Destée, A., Farrer, M.J. (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. *Am J Hum Genet* 89(3), 398-406.
- Melemedijian, O.K., Asiedu, M.N., Tillu, D.V., Sanoja, R., Yan, J., Lark, A., Khoutorsky, A., Johnson, J., Peebles, K.A., Lepow, T., **Sonenberg, N.**, Dussor, G., and Price, T.J. (2011) Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. *Molecular Pain* 7, 70.
- Fabian, M.R., Cieplak, M.K., Frank, F., Morita, M., Green, J., Srikumar, T., Nagar, B., Yamamoto, T., Raught, B., Duchaine, T.F., and **Sonenberg, N.** (2011) miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. *Nature Struct Mol Biol* 18(11), 1211-1217.
- Vosler, P.S., Gao, Y., Brennan, C.S., Yanagiya, A., Gan, Y., Cao, G., Zhang, F., Morley, S.J., **Sonenberg, N.**, Bennett, M.V., and Chen, J. (2011) Ischemia-induced calpain activation causes eukaryotic (translation) initiation factor 4G1 (eIF4GI) degradation, protein synthesis inhibition, and neuronal death. *Proc Natl Acad Sci USA* 108(44), 18102-18107.
- Fujiwara, T., Fukao, A., Sasano, Y., Matsuzaki, H., Kikkawa, U., Imataka, H., Inoue, K., Endo, S., **Sonenberg, N.**, Thoma, C., and Sakamoto, H. (2011) Functional and direct interaction between the RNA binding protein HuD and active Akt1. *Nucleic Acids Res*. Epub ahead of print. PMID 22075994
- Marcet-Palacios, M., Duggan, B.L., Shostak, I., Barry, M., Geskes, T., Wilkins, J.A., Yanagiya, A., **Sonenberg, N.**, and Bleackley, R.C. (2011) Granzyme B inhibits vaccinia virus production through proteolytic cleavage of eukaryotic initiation factor 4 gamma 3. *PLoS Pathog* 7(12):e1002447.
- Delbes, G., Yanagiya, A., **Sonenberg, N.**, and Robaire, B. (2011) PABP interacting protein 2A (PAIP2A) regulates specific key proteins during spermiogenesis in the mouse. *Biol Reprod* (Epub ahead of print). PMID 22190698

Reviews:

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

- Parsyan, A., Svitkin, Y., Shahbazian, D., Gkogkas, C., Lasko, P., Merrick, W.C., and **Sonenberg, N.** (2011) mRNA helicases: the tacticians of translational control. *Nat Rev Mol Cell Biol* 12(4), 235-245.
- Topisirovic, I., Svitkin, Y.V., **Sonenberg, N.**, and Shatkin, A.J. (2011) Cap and cap-binding proteins in the control of gene expression. *Wiley Interdiscip Rev RNA* 2(2), 277-298.
- Topisirovic, N., and **Sonenberg, N.** (2011) Translational control by the eukaryotic ribosome. *Cell* 145(3), 333-334.
- Fabian, M.R., Svitkin, Y.V., and **Sonenberg, N.** (2011) An efficient system for Let-7 microRNA and GW182 protein-mediated deadenylation in vitro. *Methods Mol Biol* 725, 207-217.
- Burley, S.K., and **Sonenberg, N.** (2011) Gimme phospho-serine five! Capping enzyme guanylyltransferase recognition of the RNA polymerase II CTD. *Mol Cell* 43(2), 163-165.
- Topisirovic, I., and **Sonenberg, N.** (2011) mRNA translation and energy metabolism in cancer: The role of the MAPK and mTORC1 pathways. *Cold Spring Harb Symp Quant Biol*. Epub ahead of print. PMID 22123850.

ST-PIERRE, Julie, Dr.

URL:

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=St+Pierre%2C+Julie%5BFull+Author+Name%5D>

- Austin, S., Klimcakova, E. and **St-Pierre, J.** (2011). Impact of PGC-1alpha on the topology and rate of superoxide production by the mitochondrial electron transport chain. *Free Radical Biology & Medicine* 51 (12), 2243-2248. Impact factor: 5.7

TEODORO, Jose, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Teodoro%20J.G%20%5bAuthor%5d>

- L. Smolders and **J.G. Teodoro.** (2011). Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy. *Expert Opinion on Therapeutic Targets*. Jun;15(6):767-80.
- T.J. Kucharski, I. Gamache, O. Goerup, and **J.G. Teodoro.** (2011). Nuclear localization of CAV-Apoptin is triggered by DNA damage signalling. *Journal of Virology*. Dec;85(23):12638-49.

TREMBLAY, Michel, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Tremblay%20ML%20%5bAuthor%5d>

- Julien SG, Dubé N, Hardy S, **Tremblay ML.** Inside the human cancer tyrosine phosphatome. *Nat Rev Cancer*. 2011 Jan;11(1):35-49. Review.
- Martin KR, Xu Y, Looyenga BD, Davis RJ, Wu CL, **Tremblay ML,** Xu HE, MacKeigan JP Identification of PTPsigma as an autophagic phosphatase. *J Cell Sci*. 2011 Mar 1;124(Pt 5):812-9. Epub 2011 Feb 8.

- Raven JF, Williams V, Wang S, **Tremblay ML**, Muller WJ, Durbin JE, Koromilas AE. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. *Cell Cycle*. 2011 Mar 1;10(5):794-804.
- El-Kouhen K, **Tremblay ML**. PTPMT1: Connecting Cardiolipin Biosynthesis to Mitochondrial Function. *Cell Metab*. 2011 Jun 8;13(6):615-7.
- Serge Hardy, Sofi G. Julien and **Michel L. Tremblay**. Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer. *Anticancer Agents Med Chem*. 2011 Jun 27. [Epub ahead of print]
- Doody KM, Bussi eres-Marmen S, Li A, Paquet M, Henderson JE, **Tremblay ML**. T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice. *Arthritis Rheum*. 2011 Oct 3. doi: 10.1002/art.33399. [Epub ahead of print].
- Sangwan V, Abella J, Lai A, Bertos N, Stuibl M, **Tremblay ML**, Park M. Protein tyrosine phosphatase PTP1B modulates early endosome fusion and trafficking of Met and EGF receptor tyrosine kinases. *J Biol Chem*. 2011 Nov 1.
- Wiede F, Shields BJ, Chew SH, Kyparissoudis K, van Vliet C, Galic S, **Tremblay ML**, Russell SM, Godfrey DI, Tiganis T. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. *J Clin Invest*. 2011 Dec 1;121(12):4758-74. Epub 2011 Nov 14.
- Berdnikovs S, Pavlov VI, Abdala-Valencia H, McCary CA, Klumpp DJ, **Tremblay ML**, Cook-Mills JM. PTP1B Deficiency Exacerbates Inflammation and Accelerates Leukocyte Trafficking In Vivo. *J Immunol*. 2012 Jan 15;188(2):874-84. Epub 2011 Dec 9.

YANG, Xiang-Jiao, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20XJ.%20%5bAuthor%5d%20Montreal>

Aka, J.A., Kim, G.W., and **Yang, X.J.** (2011) K-acetylation and its enzymes: overview and new developments. *Handb Exp Pharmacol*. 206, 1-12. (Review article)

ZANNIS-HADJOPOULOS, Maria, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Zannis-Hadjopoulos%20M%20%5bAuthor%5d>

Sideridou, M., Zakopoulou, R., Evangelou, K., Liontos, M., Kotsinas, A., Rampakakis, E., Tan, E.-J., Kahata, Grabusic, K., Aggarwal, V., Zompourlis, V., Gkouskou, K., Gagos, S., Levy, B., Trougakos, I., Volarevic, S., Kolettas, E., Eliopoulos, A., **Zannis-Hadjopoulos, M.**, Moustakas, A. and Gorgoulis, V.G. (2011). Oncogenic Cdc6 acts as a “molecular switch” at the CDH1(E-cadherin) locus promoting epithelial carcinogenesis. *J. Cell Biol.*, 195:1123-1140.

Book chapters:

Zannis-Hadjopoulos, M. and Rampakakis, E. (2011). Synergy between DNA Replication and Repair Mechanisms. Chapter for book on ‘DNA Repair/Book 1-On the Pathways to Fixing DNA Damage and Errors, ISBN 978-953-307-649-2, edited by Francesca Storici’, InTech online publishers

ZOGOPOULOS, George, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Zogopoulos%20G%20%5BAuthor%5D%20>

Holter S., Pollett A., **Zogopoulos G.**, Kim H., Schwenter F., Asai K., Gallinger S., Clendenning M., Steinbach G., Jacobson A., Boycott K.M. Hepatic Adenomas Caused by Somatic TCF1 Mutations in Children with Biallelic Mismatch Repair Gene Mutations. *Gastroenterology* 140(2):735-6, 2011.

Appendix V – Service outside McGill: academic and community engagement

BEAUCHEMIN, Nicole

Grant panels

Member, FRSQ, Senior Scholarship, 2001-2011, 1 day/yr

Member, CIHR, Cancer Progression and Therapeutics Committee, 2008-2011, 4 days/yr

Chair, CIHR, Cancer Progression and Therapeutics Committee, 2011-present, 10 days/yr

Ad hoc reviewer, FRSQ Centre visiting committee member, 2009-2011

Meeting organizer, the Montreal International Symposium on Angiogenesis and Metastasis, 2009-2011 (> 200 participants)

Talks to lay audiences

Cancer Research Society, 5 nights between November 2010 and February 2011, speaking to volunteers about breast cancer experience and colon cancer research.

La Différence, Granby, QC, April 21, 2011

SCC, Terrebone, QC, April 27, 2011

SCC, Baie-Comeau, QC, April 30, 2011

BOUCHARD, Maxime

Grant panels

Member, Kidney Foundation of Canada, Biomedical Research, 2007-2011

Member, FRSQ-Junior 2, 2011-present

Ad hoc reviewer, March of Dimes (USA), 2011

BRANTON, Philip

Member, Canadian Cancer Society-University of New Brunswick Research Chair Search Committee, 2010-2011.

Chair, International Advisory Board, University Hospital Network, University of Toronto, 2006-present.

Member, National Research Council Cancer Advisory Committee, Protein Therapeutics Group, Biotechnology Research Institute, Montreal, QC, 2008-present.

Member, Advisory Board, Canadian Tumour Repository Network, 2010-present.

Member, Review Board, Integrated Cancer Research Sites (SIRIC), Institut national du cancer (INCa, Paris, France), 2010-present.

Chair, Scientific Advisory Committee, Terry Fox Research Institute, 2008-present.

DUCHAINE, Thomas

Session organizer, RNA control of translation session for the 2011 RiboClub opening session, Sept. 19-21, 2011. Upon invitation by Riboclub chair Sherif Abou Elela, I organized a session on small RNAs. As such, I selected and invited speakers for the session.

Invited Chair, Epigenetics eh! Meeting, London, Ontario, May 4, 2011.

GALLOUZI, Imed

CIHR, permanent member of BCA panel, 2009-present

Editor, PLoS One, 2011-present

Editor, Aging, 2010-present

Co-chair, mRNA Granule Session with Rachid Mazroui, in the 5th Int. Congress on Stress Responses, Biology & Medicine., Quebec City, Canada, Aug. 21-25, 2011.

GIGUERE, Vincent

Editorial boards

Molecular Endocrinology, 1995-1998, 2007-2009, 2010-2012

American Journal of Cancer Research, 2011-present

Contributor, Faculty of 1000, Cell Biology, 2008-present

Grant review committees

Susan G. Komen for the Cure: 2011 Investigator-Initiated Research (IIR) Grants, Novel Therapeutics and/or Resistance: Targeted Therapies for Triple Negative Breast Cancer.

CCSRI, Member, Grant Panel D, Cell and Molecular Biology (Endocrinology and Receptors) 2009-2011.

FRSQ, Evaluation 2011, Groupes de recherche du FRSQ (IRCM).

Member, Abstract review committee, 93rd Annual Meeting of the Endocrine Society, Boston, MA, USA, June 2011.

GROS, Philippe

Burroughs-Wellcome Fund, Advisory Committee, "Investigators in Infectious Diseases Program" 2003-present.

McLaughlin-Rotman Center for Global Health, University Health Network, University of Toronto, Member, External Advisory Board, 2004-present.

Invited Presentations at Symposia/Meetings

Keystone Symposium: Tuberculosis. Vancouver, Canada, Jan 19, 2011

World Immunology Conference: A Global Get-Together, New York, NY, June 2-4, 2011

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

International Symposium on Angiogenesis and Metastasis, Montreal, Canada, June 14-17, 2011

Third Genetic Conference on Host Genetic Control of Infectious Diseases, Paris, France, Sept 27-Oct 1, 2011

Invited Presentations to Institutions

Rockefeller University, New York, NY (Dr. J.L. Casanova), May 18, 2011

University of Toronto, Microbiology Research Day (Dr. K. Kain), June 14, 2011

Montreal Children's Hospital, MUHC (Dr. G. Tannenbaum), Nov 21, 2011

Public Health Research Institute, Newark, NJ (Dr. Issarr Smith), Nov 22, 2011

Editorial Board membership

The Journal of Experimental Medicine, Advisory Editor, 2007-present

Genes and Immunity, Senior Editor, 2000-present

Mammalian Genome, Editorial Board Member, 2003-present

Funding Agencies review committees

Canadian Gene Cure Foundation, Scientific Director, Board Member, Grant panel Director, 2007-2011

Bill and Melinda Gates Foundation, Grand Challenges Explorations Program, Evaluation Panel, 2009-present

CIHR, Institute of Genetics, Institute Advisory Board, 2005- 2011

CIHR, Panel Member, Knowledge Diffusion Grant Committee 2011-present

Meeting Organization

Annual Canadian Conference of Human Genetics, Banff, Alberta, Organizing Committee, 2011

HALLETT, Michael

Grant panels

Ontario Genomics Research Council, 2010-2011

Terry Fox Cancer Research Society, 2011

CIHR Strategic Group for Epigenomics and Personalized Medicine, 2011

Invited lectures

Oslo, Norway, Invited Seminar: The existence of inherently difficult prognostic breast cancer patients, 2011.

Vancouver Oncology-Bioinformatics Meeting: A fresh perspective on prognostic prediction in breast cancer, 2011.

Review committees

External reviewer, Department of Molecular Genetics, University of Toronto, 2011.

JONES, Russell

Member, CIHR grant panel: Cancer Biology and Therapeutics, 2009-present

McCAFFREY, Luke

Reviewer, Journal of Cell Biology, 2009-present

Reviewer, Faculty of 1000, 2009-present

Ad hoc reviewer, Canada Foundation for Innovation, 2011

Reviewer, Panel C, Cancer Research Society, 2011

Poster evaluator, MISAM 2011, June 16, 2011

Poster evaluator, Canadian Cancer Research Conference, November 27-30, 2011

MULLER, William

Grant and Personnel Committees

Member, Scientific NIH PPG Advisory Panel, UCSF, 2000-present

Member, Scientific NIH PPG Advisory Panel, Ohio State, 2001-present

Member, Scientific NIH Advisory Panel, Albert Einstein School of Medicine, 2002-present

Member, US Army Integration Panel, 2005-present

Chair, CRS Panel D, 2010-present

NEPVEU, Alain

Editorial Board, Gene, 2011-present

Video interview for the Canadian Cancer Society (2:50’):

http://www.cancer.ca/Quebec/Cancer%20research/Meet%20our%20researchers/QC-In%20Quebec/Dr_Alain_Nepveu.aspx?

Interview for The Gazette, January 2011

Interview on CBC International, 5’, February 2011

Interview for Le Devoir, February 2011

PARK, Morag

SickKids Research Institute, Cell Biology Program External Review, Toronto, 2011.

Co-chair, Scientific Program Committee, Canadian Cancer Research Conference, Toronto, Ontario, Canada, 2011.

Member, Gairdner Foundation Medical Review Panel, 2011-2014.

Member, Cancer Stem Cell Consortium (CSCC), 2008-present.

Co-chair, Board of the Canadian Cancer Research Alliance (CCRA), 2009-2011.

Member, WHO-International Agency for Cancer Research (IARC), Governing Council, Lyon, France, 2008-present.

PAUSE, Arnim

Grant panels

Member, Operating Grant Panel, Kidney Foundation of Canada, 2010-present
Member, Research Award Committee, von Hippel-Lindau Family Alliance, 2009-present
Member, CIHR operating grant panel, Cancer Biology and Therapeutics (CBT), 2008-2011
Member, Research Award Committee, von Hippel-Lindau Family Alliance, 2009-present
Member, Research Award Committee, Canadian Liver Foundation, 2008-present
Member, College of Reviewers for CRC chairs, 2005-present
Reviewer, Saskatchewan Health Research Foundation, 2007-present
Mentor and Member, Canadian National Hepatitis C Research Training Program (NC RTP-HepC), 2005-present

Tutor in the Marianopolis College Lab Project. In this project I supervise 6 college science students for two days in a project in my lab. This is the first experience for these students in a research lab and they are exposed to the various technologies we use. After the two days they have to write a report about their experience which I help grading together with their science teachers. 2006-present.

Science fair Judge at Royal West Academy High School, Montreal West, Quebec, 2007-present.

SHORE, Gordon

MICTRP – Career Exploration Workshop

SIEGEL, Peter

Grant panels

CIHR Panel C, New Investigator Awards, 2011
CCSRI, Panel II, Research Grant Competition, Innovation, 2011

Ad hoc reviews

Clinical Cancer Res, Current Medicinal Chemistry, EMBO Journal, Expert Opinion in Biological Therapy, Genes & Development (2), International Journal of Cancer, Molecular Cellular Biology

SONENBERG, Nahum

Editorial Board, WIRES RNA, 2010-present
Editorial Board, Current Opinions in Cell Biology, 2011-present

ST-PIERRE, Julie

Grant reviews

Panel Member, CRS, 2010-present, 2 days/year

Panel Member, FRSQ, bourses de formation postdoctorale, 2011-present, 2 days/year

Reviewer, CIHR, Cancer Progression & Therapeutics, Fall 2011

Reviewer, Agence Nationale de la Recherche Scientifique, France, 2011

TEODORO, Jose

Editorial Board, Oncology Letters, 2009-present

Grant Reviews Panel Member

CIHR, Doctoral Research Award A (DRA) Committee, 2008-present

CIHR, Master's Awards A (CGA) Committee, 2008-present

CIHR, Molecular and Cellular Biology of Cancer (MCC), 2010-present

FRSQ, Junior 1 Salary Awards, 2010-present

Ad hoc reviews

PLoS One (2 reviews), July 2010, Aug 2011

Cell Death and Differentiation, Sept 2011

TREMBLAY, Michel

Section Editor, Current Oncology, 2007-present

Member, Board of Directors, MISPRO Inc., 2003-present

Member, Canada Research Chairs' College of Reviewers, 2001-present

Member, Organizing Committee, Eight World Congress on Animal Research, Montreal, 2011

Chair, Advisory Committee for the TFRI Node, Jan 2010 to 2011

Member, Advisory Committee on Research (ACOR), Canadian Cancer Society, 2009-present

Membre, Comité exécutif, FRSQ, 2006-2011

Membre du conseil d'administration, FRSQ, 2004-2011

Scholarships Panel Member, Canderel Fellowship, Studentship and Fellowship, 1995-present

Grant Panel Member, CFI, New Opportunities Fund (NOF) College of Reviewers, 2004-present

YAMANAKA, Yojiro

Journal reviews

Nature Protocols, May 2011

FASEB J., Mar 2011

EMBO J., Mar 2011

Developmental Cell, Mar 2011

Development, Sept 2011

Rosalind and Morris Goodman Cancer Centre Annual Report 2011

Molecular Human Reproduction, Jan 2011

Grant review

Czech Science Foundation (as an external expert), Aug 2011

YANG, Xiang-Jiao

Editorial Board Member, Genes & Cancer, 2009-present

Advisory Board Member, Biochem. J., 2010-present

Grant Panel, CIHR Postdoctoral Fellowship Review Committee Member, 2011-present

Ad hoc grant reviews

NSERC

Israel Science Foundation (ISF)

Research Grants Council, Hong Kong

National Science Council, Taiwan

Ad hoc peer reviews for various scientific journals.

ZANNIS-HADJOPOULOS, Maria

Member, Editorial Board, International Society for Gene Therapy & Molecular Biology, 1997-present

Member, Organizing Committee/Scientific Advisory Board of the Annual Conferences, International Society for Gene, 1997-present

Site visit, Centre for Epigenetics, Danish Res. Foundation, Copenhagen, Denmark, January 12-13, 2011

External Reviewer, European Science Foundation//EUROCORES

Member, Academic Committee, Hellenic Scholarships Foundation

Evaluator of grant applications submitted to the Greek Ministry of Research and Technology

Member, Hellenic Quality Assurance Agency for Higher Education (H.Q.A.A.), evaluations of Departments in the field of Life Sciences.

ZOGOPOULOS, George

Member, Research Committee, American Hepato-Pancreato-Biliary Association, 2011-2013.

Section III

Confidential Information